Exicure Inc (XCUR)

Overview News Price History Discussions Forecast Stock Split

Exicure Inc stock is currently priced at $0.5403, with a 24-hour trading volume of 6,200. It has seen a +0.11% increased in the last 24 hours and a -14.05% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.5489 pivot point. If it approaches the $0.5258 support level, significant changes may occur.

Exicure Inc Stock (XCUR) Financials Data

Exicure Inc (XCUR) Revenue 2024

XCUR reported a revenue (TTM) of $28.83 million for the quarter ending December 31, 2022, a +6,068% rise year-over-year.

Exicure Inc (XCUR) Net Income 2024

XCUR net income (TTM) was $3.06 million for the quarter ending June 30, 2023, a +105.76% increase year-over-year.

Exicure Inc (XCUR) Cash Flow 2024

XCUR recorded a free cash flow (TTM) of -$21.95 million for the quarter ending June 30, 2023, a +29.60% increase year-over-year.

Exicure Inc (XCUR) Earnings per Share 2024

XCUR earnings per share (TTM) was $1.68 for the quarter ending June 30, 2023, a +110.31% growth year-over-year.

Exicure Inc Stock (XCUR) Latest News

Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Benzinga

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.